American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 897-906 , November 2008

Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-analysis

  • Benaya Rozen-Zvi, MD

      Affiliations

    • Department of Nephrology and Hypertension, Tel Aviv University, Tel-Aviv, Israel
    • Corresponding Author InformationAddress correspondence to Benaya Rozen-Zvi, MD, Department of Nephrology, and Hypertension, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel
    • ,
  • Anat Gafter-Gvili, MD

      Affiliations

    • Department of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel
    • ,
  • Mical Paul, MD

      Affiliations

    • Infectious Disease Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel
    • ,
  • Leonard Leibovici, MD

      Affiliations

    • Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, and the Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
    • ,
  • Ofer Shpilberg, MD

      Affiliations

    • Department of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel
    • ,
  • Uzi Gafter, MD, PhD

      Affiliations

    • Department of Nephrology and Hypertension, Tel Aviv University, Tel-Aviv, Israel

Received 31 January 2008 ,Accepted 21 May 2008.

References 

  1. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  2. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504–510
  3. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134
  4. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin (Results of a combined phase I and II clinical trial). N Engl J Med. 1987;316:73–78
  5. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease (Results of a phase III multicenter clinical trial). Ann Intern Med. 1989;111:992–1000
  6. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989;299:157–158
  7. Danielson B. R-HuEPO hyporesponsiveness—Who and why?. Nephrol Dial Transplant. 1995;10(suppl 2):S69–S73
  8. Sunder-Plassmann G, Horl W. Erythropoietin and iron. Clin Nephrol. 1997;47:141–157
  9. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int. 1989;35:712–716
  10. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234–238
  11. Fishbane S. Iron supplementation in renal anemia. Semin Nephrol. 2006;26:319–324
  12. Horl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007;18:382–393
  13. Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis. 2000;36:88–97
  14. Walters BA, Van Wyck DB. Benchmarking iron dextran sensitivity: Reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant. 2005;20:1438–1442
  15. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 2004;65:2108–2112
  16. Brewster UC, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial. 2004;17:57–60
  17. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40:90–103
  18. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279–2289
  19. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendation for Anemia in Chronic Kidney Disease in Adults. Am J Kidney Dis. 2006;47(suppl 3):S11–S145
  20. Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):Sii1–Sii47
  21. Gillespie RS, Wolf FM. Intravenous iron therapy in pediatric hemodialysis patients: A meta-analysis. Pediatr Nephrol. 2004;19:662–666
  22. Notebaert E, Chauny JM, Albert M, Fortier S, Leblanc N, Williamson DR. Short-term benefits and risks of intravenous iron: A systematic review and meta-analysis. Transfusion. 2007;47:1905–1918
  23. In:  Higgins JPTGS editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, UK: Wiley; 2005;
  24. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  25. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias (Dimensions of methodological quality associated with estimates of treatment effects in controlled trials). JAMA. 1995;273:408–412
  26. Warady BA, Kausz A, Lerner G, et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol. 2004;19:655–661
  27. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron. 1991;57:175–182
  28. Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif. 2008;26:151–156
  29. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–46
  30. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694–1699
  31. Michael B, Trout JR, Horl WH, Volinn W, Jorjensen N, Dahl NV. Effectiveness of continuous low-dose intravenous ferric gluconate therapy for maintaining Hb and decreasing epoetin requirement in hemodialysis patients. J Am Soc Nephrol. 2007;18:289A;(abstr)
  32. Svara F, Sulkova S, Kvasnicka J, Polakovic V. Iron supplementation during erythropoietin therapy in patients on hemodialysis. Vnitr Lek. 1996;42:849–852
  33. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55–c62
  34. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26:445–454
  35. Aggarwal HK, Nand N, Singh S, Singh M, Hemant , Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003;51:170–174
  36. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846–2856
  37. Spinowitz BS, Besarab A, Bolton WK, et al. Ferumoxytol as an intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis—Evaluation of safety and efficacy in two phase III studies. J Am Soc Nephrol. 2006;17:342A;(abstr)
  38. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967–974
  39. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis. 2007;49:736–743
  40. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998;13:82–88
  41. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int. 2006;69:1259–1263
  42. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006;1(suppl 1):S19–S23
  43. Zager RA. Parenteral iron compounds: Potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol. 2006;1(suppl 1):S24–S31
  44. Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N, Goldstein M. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol. 2007;2:688–693

 B.R.Z and A.G.-G. contributed equally to this work.

 Originally published online as doi:10.1053/j.ajkd.2008.05.033 on October 9, 2008.

PII: S0272-6386(08)01060-3

doi: 10.1053/j.ajkd.2008.05.033

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 897-906 , November 2008

Article Tools

* Image Usage & Resolution